BriaCell Therapeutics Corp. SEC filings BCTX
BriaCell Therapeutics Corp. has 324 filings in SEC EDGAR's recent list, going back to Jun 20, 2014. Its latest annual report, Form 10-K, was filed on Oct 28, 2026 for the period ended Jul 31, 2026. The latest quarterly report (Form 10-Q) was filed on Jun 9, 2026, covering the quarter ended Apr 30, 2026. The most recent current report (Form 8-K) was filed on Jun 26, 2026 (regulation fd disclosure). The company's fiscal year ends on July 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 25-NSE | Delisting notice | Feb 26, 2026 | — |
| EFFECT | Filing | Jan 13, 2026 | — |
| CERT | Filing | Jan 13, 2026 | — |
| 8-A12B | Filing | Jan 13, 2026 | — |
| CORRESP | Letter to the SEC | Jan 8, 2026 | — |
| CORRESP | Letter to the SEC | Jan 8, 2026 | — |
| CORRESP | Letter to the SEC | Jan 6, 2026 | — |
| CORRESP | Letter to the SEC | Jan 6, 2026 | — |
| DRSLTR | Filing | Oct 16, 2025 | — |
| DRS | Filing | Oct 16, 2025 | — |
| EFFECT | Filing | Jul 15, 2025 | — |
| CORRESP | Letter to the SEC | Jul 15, 2025 | — |
| CORRESP | Letter to the SEC | Jul 15, 2025 | — |
| CORRESP | Letter to the SEC | Jul 14, 2025 | — |
| CORRESP | Letter to the SEC | Jul 14, 2025 | — |
| CORRESP | Letter to the SEC | Jul 11, 2025 | — |
| CORRESP | Letter to the SEC | Jul 11, 2025 | — |
| CORRESP | Letter to the SEC | Jul 8, 2025 | — |
| CORRESP | Letter to the SEC | Jul 8, 2025 | — |
| UPLOAD | Letter from the SEC | Jun 24, 2025 | — |
| DRSLTR | Filing | Jun 18, 2025 | — |
| DRS | Filing | Jun 18, 2025 | — |
| EFFECT | Filing | Apr 24, 2025 | — |
| CERT | Filing | Apr 24, 2025 | — |
| 8-A12B | Filing | Apr 24, 2025 | — |
| CORRESP | Letter to the SEC | Apr 22, 2025 | — |
| CORRESP | Letter to the SEC | Apr 22, 2025 | — |
| CORRESP | Letter to the SEC | Apr 22, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 24, 2025 | — |
| DRSLTR | Filing | Mar 12, 2025 | — |
| DRS | Filing | Mar 12, 2025 | — |
| EFFECT | Filing | Jan 31, 2024 | — |
| CORRESP | Letter to the SEC | Jan 29, 2024 | — |
| UPLOAD | Letter from the SEC | Jan 29, 2024 | — |
| EFFECT | Filing | Mar 28, 2023 | — |
| UPLOAD | Letter from the SEC | Mar 16, 2023 | — |
| CORRESP | Letter to the SEC | Mar 13, 2023 | — |
| UPLOAD | Letter from the SEC | Mar 8, 2023 | — |
| EFFECT | Filing | Mar 16, 2022 | — |
| EFFECT | Filing | Nov 23, 2021 | — |
| EFFECT | Filing | Jun 24, 2021 | — |
| CORRESP | Letter to the SEC | Jun 22, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 21, 2021 | — |
| D | Filing | Jun 15, 2021 | — |
| EFFECT | Filing | Feb 23, 2021 | — |
| CERT | Filing | Feb 23, 2021 | — |
| 8-A12B | Filing | Feb 23, 2021 | — |
| CORRESP | Letter to the SEC | Feb 18, 2021 | — |
| CORRESP | Letter to the SEC | Feb 18, 2021 | — |
| CORRESP | Letter to the SEC | Feb 18, 2021 | — |
| CORRESP | Letter to the SEC | Feb 2, 2021 | — |
| UPLOAD | Letter from the SEC | Feb 1, 2021 | — |
| CORRESP | Letter to the SEC | Jan 14, 2021 | — |
| CORRESP | Letter to the SEC | Dec 22, 2020 | — |
| UPLOAD | Letter from the SEC | Dec 21, 2020 | — |
| CORRESP | Letter to the SEC | Dec 10, 2020 | — |
| UPLOAD | Letter from the SEC | Oct 23, 2020 | — |
| CORRESP | Letter to the SEC | Oct 20, 2020 | — |
| UPLOAD | Letter from the SEC | Oct 16, 2020 | — |
| CORRESP | Letter to the SEC | May 27, 2020 | — |
| CORRESP | Letter to the SEC | May 15, 2020 | — |
| CORRESP | Letter to the SEC | Mar 13, 2020 | — |
| UPLOAD | Letter from the SEC | Mar 9, 2020 | — |
| CORRESP | Letter to the SEC | Nov 27, 2019 | — |
| UPLOAD | Letter from the SEC | Nov 22, 2019 | — |
| CORRESP | Letter to the SEC | Nov 12, 2019 | — |
| UPLOAD | Letter from the SEC | Nov 8, 2019 | — |
| DEL AM | Filing | Nov 6, 2019 | — |
| CORRESP | Letter to the SEC | Oct 22, 2019 | — |
| UPLOAD | Letter from the SEC | Oct 1, 2019 | — |
| DRS | Filing | Aug 30, 2019 | — |
| D | Filing | Apr 10, 2018 | — |
| D | Filing | Dec 12, 2014 | — |
| D | Filing | Jun 20, 2014 | — |
Showing 74 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BCTX (Nasdaq), BCTXL (Nasdaq), BCTXZ (Nasdaq)
- Fiscal year ends
- July 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- West Vancouver, British Columbia, Canada
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1610820
- Former names
- Ansell Capital Corp. (until Jun 20, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.